TICAGRELOR TREATMENT FOR PREVENTION OF CARDIOVASCULAR EVENTS IN HIGH RISK POST MYOCARDIAL INFARCTION PATIENTS- COST-EFFECTIVENESS ANALYSIS USING EVIDENCE FROM THE PEGASUS-TIMI 54 TRIAL
Author(s)
Moore P1, Briggs A2, Davies A3, Sculpher M4, Kun K5, Magnuson EA6, Cohen DJ6, Mellstrom C7
1Commercial Eyes, MELBOURNE, Australia, 2Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK, 3ICON Health Economics & Epidemiology, Oxford, UK, 4University of York, Heslington, York, UK, 5AstraZeneca, Södertälje, Sweden, 6Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, 7AstraZeneca, Mölndal, Sweden
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCV107
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now